Expert perspectives on the optimal management of a woman who is diagnosed and relapses with diffuse large B-cell lymphoma.
EP. 1: A Case of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Expert hematologist/oncologist Daniel O. Persky, MD, reviews the case of a 73-year-old woman who is diagnosed with and treated for DLBCL, later to relapse and require novel therapy.
EP. 2: Diffuse Large B-Cell Lymphoma: Frontline Treatment Options
A review of frontline treatment options for DLBCL informed by comprehensive patient workup and the efficacy of available therapies.
EP. 3: Optimal Second-Line Therapy for Diffuse Large B-Cell Lymphoma
Daniel O. Persky, MD, reflects on a patient’s relapse with diffuse large B-cell lymphoma and the rationale behind treatment with polatuzumab + BR.
EP. 4: The GO29365 Trial: Polatuzumab + BR in R/R DLBCL
Expert insight on the GO29365 trial, which informs selection of polatuzumab + bendamustine and rituximab in patients with relapsed/refractory DLBCL.
EP. 5: Future Therapeutic Options for Diffuse Large B-Cell Lymphoma
Considering a patient’s relapse and potential response to therapy, Daniel O. Persky, MD, looks forward to the future use of novel therapies in diffuse large B-cell lymphoma.
2 Commerce Drive Cranbury, NJ 08512